Edition:
United States

Biotechnology & Medical Research

Page 1

Immunocellular Therapeutics Announces Review Of Strategic Alternatives

Thursday, 22 Feb 2018 06:00am EST

Feb 22 (Reuters) - Immunocellular Therapeutics Ltd ::IMMUNOCELLULAR THERAPEUTICS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES.IMMUNOCELLULAR THERAPEUTICS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES.IMMUNOCELLULAR THERAPEUTICS - RETAINED LADENBURG THALMANN & CO AS STRATEGIC FINANCIAL ADVISOR TO ASSIST IN REVIEW OF BUSINES, ASSETS.IMMUNOCELLULAR THERAPEUTICS - REVIEW OF STRATEGIC OPPORTUNITIES COULD INCLUDE POTENTIAL SALE OR MERGER OF COMPANY.

Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11‍​

Friday, 9 Feb 2018 06:30am EST

Feb 9 (Reuters) - Immunogen Inc ::IMMUNOGEN REPORTS PIPELINE PROGRESS AND 2017 OPERATING RESULTS.QTRLY NET LOSS PER COMMON SHARE, BASIC AND DILUTED $0.11‍​.SEES FY 2018 REVENUE $60 MILLION TO $65 MILLION.QTRLY TOTAL REVENUES $39.45 MILLION VERSUS $13.85 MILLION.IMMUNOGEN - EXPECTS CURRENT CASH COMBINED WITH EXPECTED CASH REVS FROM PARTNERS & COLLABORATORS WILL ENABLE CO TO FUND ITS OPERATIONS INTO Q4 OF 2019.Q4 EARNINGS PER SHARE VIEW $-0.12, REVENUE VIEW $32.7 MILLION -- THOMSON REUTERS I/B/E/S.SEES CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2018 BETWEEN $115 MILLION AND $120 MILLION.FY2018 REVENUE VIEW $58.7 MILLION -- THOMSON REUTERS I/B/E/S.IMMUNOGEN SAYS TO MOVE TO OPERATING MODEL THAT WILL RELY ON EXTERNAL MANUFACTURING AND QUALITY TESTING FOR DRUG SUBSTANCE.IMMUNOGEN - TO MOVE TO OPERATING MODEL THAT WILL ALSO RELY ON EXTERNAL MANUFACTURING AND QUALITY TESTING FOR DRUG PRODUCT FOR DEVELOPMENT PROGRAMS.DECOMMISSIONING NORWOOD FACILITY WILL RESULT IN ANTICIPATED COST SAVINGS OF OVER $20 MILLION DURING NEXT FIVE YEARS.IMMUNOGEN -IMPLEMENTING ‍NEW OPERATING MODEL TO LEAD TO RAMP-DOWN OF MANUFACTURING, QUALITY ACTIVITIES AT NORWOOD, MASSACHUSETTS FACILITY BY 2018 END​.‍ IMPLEMENTATION OF NEW OPERATING MODEL WILL LEAD TO FULL EXIT AT NORWOOD, MASSACHUSETTS FACILITY BY EARLY 2019​.Q4 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.

Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business‍​

Monday, 22 Jan 2018 08:14am EST

Jan 22 (Reuters) - Flex Pharma Inc ::FLEX PHARMA - ENGAGED INVESTMENT BANKING FIRM TO ASSIST WITH CONSIDERATION OF STRATEGIC ALTERNATIVES FOR CO'S HOTSHOT CONSUMER PRODUCT BUSINESS‍​.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary